<DOC>
	<DOCNO>NCT01544348</DOCNO>
	<brief_summary>Phase 1 study evaluate safety MEDI4212 .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Placebo-controlled , Dose-escalation Safety Study MEDI4212 Subjects With IgE &gt; = 30 IU/mL</brief_title>
	<detailed_description>A Phase 1 , randomize , placebo-controlled , dose-escalation study evaluate safety tolerability ascend single subcutaneous intravenous dos MEDI4212 subject immunoglobulin E ( IgE ) great equal ( &gt; = ) 30 international unit per milliliter ( IU/mL ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Age 18 60 year Written inform consent locally require authorization Body weight 45150 kilogram ( kg ) Cohorts 13 , 4b , 59 . Body weight 4590 kg Cohort 4a Females must surgically sterilize postmenopausal Nonsterilized male sexually active female partner childbearing potential must use highly effective method contraception Day 1 Day 85 ; Both partner use contraception Sterilized male must least 1year post vasectomy use highly effective contraceptive method Healthy Japanese population determine responsible physician Current diagnosis allergic rhinitis , allergic asthma , atopic dermatitis ( cohorts 16 ) diagnostic immunoglobulin E ( IgE ) 30 international unit per milliliter ( IU/mL ) Screening . Diagnostic IgE level restrict subject enrol cohort , follow level require Screening : Cohorts 1 2 : 30700 IU/mL ; Cohort 3 : 30700 IU/mL ( 4 subject ) , great ( &gt; ) 7001,200 IU/mL ( 4 subject ) , &gt; 1,200 IU/mL ( 4 subject ) ; Cohort 4a : 30500 IU/mL ; Cohort 4b : &gt; 700 IU/mL ; Cohorts 5 6 : 30700 IU/mL ( 4 subject per cohort ) &gt; 700 IU/mL ( 6 subject per cohort ) Japanese Cohorts 79 : great equal ( &gt; = ) 30 IU/mL Nonsmoker &gt; =6 month Obsolete criterion longer require Positive vitro IgE fluorescence enzyme immunoassay ( FEIA ) response A forced expiration volume one second ( FEV1 ) &gt; = 80 percent ( % ) predict subject asthma . Nonasthmatic subject FEV1 &gt; =80 % predict , FEV1 le ( &lt; ) 80 % predict , opinion investigator , lung disease Ability willingness complete followup period Day 85 require protocol . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Concurrent enrollment another clinical study Employees clinical study site individual involve conduct study , immediate family member individual Exposure antiIgE monoclonal antibody ( MAb ) within 12 month prior Screening Positive drug screen Screening Day 1 . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepine History regular alcohol abuse within 12 month prior Screening History sensitivity component investigational product formulation history drug allergy , opinion investigator medical monitor , contraindicate participation Subjects abnormal liver function test value ( aspartate transaminase [ AST ] alanine transaminase [ ALT ] ) Screening define follow : ) Liver function test value &gt; = 1.5 time upper limit normal ( ULN ) Unwillingness inability follow procedure outline protocol Positive test history hepatitis B positive hepatitis C Positive test history human immunodeficiency virus ( HIV ) subject know HIV seropositive History cancer , exception basal cell carcinoma situ carcinoma cervix treat apparent success Women pregnant , breastfeeding , lactate Plans donate blood study period HyperIgE syndrome bronchopulmonary aspergillosis Prior history Immune Complex Disease type 3 hypersensitivity reaction MAb administration Known history prior infusion reaction MAb administration History untreated parasitic/helminthic infection within 6 month prior Screening Uses follow medication : ) Oral corticosteroid b ) Medium high dose Immunocorticosteroids ( ICS ) / longacting beta agonist ( LABA ) c ) Immunosuppressives ) Beta blocker If receive allergy immunotherapy , must stable dose 3 month . Must receive allergy immunotherapy within 7 day investigational product administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Allergic</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>MEDI4212</keyword>
</DOC>